Date & Time
Dr. Patrick Soon-Shiong and his multidisciplinary team at Nantworks aim to revolutionize how cancer is diagnosed and treated. In this third program of the Emperor of All Maladies series, Soon-Shiong will describe his vision how to integrate super computing,cloud computing, genomic analysis, and targeted drug development by transcending the genome to the proteome, to manage an individual’s cancer as a chronic but controllable disease. Through advanced rapid gene sequencing, supercomputing, proteomic analysis, and a high speed fiber optic network he has analyzed genomic data and transcriptomic data from tumor samples within minutes, then validated the predicted abnormal protein pathway by targeted proteinomics from laser dissected paraffin embedded tissue. This is the first comprehensive omic analysis of tumor and normal cells from the same tissue sample. This approach has the potential to redefine how cancer is diagnosed and is making it possible to develop therapies precisely tailored to the molecular profile of a patient’s tumor based on quantifiable protein analysis at the atomolar level. Soon-Shiong anticipates an R&D revolution in drug development, and delivery of molecularly designed cancer treatments to patients. For this program, we discussed the challenges and possible solutions for the collection and use of large amounts of data, and redefining cancer care based on molecular driven decisions.
To view a recording of this event, please click here.
Dr. Patrick Soon-Shiong has lent vision, voice, and action to the power of convergence – applying the limitless potential of collaborative science and technology on a personal level – at the speed of thought. A physician, surgeon and scientist, he has pioneered treatments for both diabetes and cancer, published over 100 scientific papers, and holds 50 US patents on groundbreaking advancements across myriad fields.
Dr. Soon-Shiong serves as Chairman of the Chan Soon-Shiong Family Foundation; Chairman and CEO of the Chan Soon-Shiong Institute for Advanced Health; the Healthcare Transformation Institute; National LambdaRail; and NantWorks, LLC – a company whose mission is to converge semiconductor technology, supercomputing, advanced networks, and proven innovation to revolutionize how we work, live and play.
Dr. Soon-Shiong has garnered vast acclaim as a visionary who has brought forth a fact-based approach to the wonders of science and the wonders of imagination – merging vision with proven application. Harnessing the power of convergence, he has an established record of achievement in bringing together people who are inspired by the impossible and believe progress begins where “possibility” ends.
Dr. Razelle Kurzrock joined UC San Diego Moores Cancer Center in November 2012 as Senior Deputy Center Director for Clinical Science and Murray Professor of Medicine. Her charge is broad, including growing and innovating the clinical trials program, and directing the Clinical Trials Office as well as the newly established Center for Personalized Therapy.
Dr. Kurzrock is best known for successfully creating the largest Phase I clinical trials department in the world while at the University of Texas M.D. Anderson Cancer Center. She was the Chair of the department designated Investigational Cancer Therapeutics from its inception until August 2012 when she moved to UC San Diego Moores Cancer Center. In FY12 alone, this department enrolled about 1,200 patients in 128 therapeutic trials. Dr. Kurzrock’s unique approach emphasized using cutting-edge molecular profiling technologies to match patients with novel targeted therapies reflecting a personalized strategy to optimize cancer treatment.